NEW YORK--(BUSINESS WIRE)--Tonix Pharmaceuticals Holding Corp. (OTCBB:TNXP) (“TONIX” or the “Company”), a specialty pharmaceutical company developing therapies for challenging disorders of the central nervous system (“CNS”), including fibromyalgia syndrome (“FM”) and post-traumatic stress disorder (“PTSD”), will initiate a comparative pharmacokinetic (“PK”) and bioavailability (“BA”) study of TNX-102, a novel dosage oral formulation of cyclobenzaprine for the treatment of FM, following the U.S. Food and Drug Administration (“FDA”) clearance of the Company’s initial Investigational New Drug Application. TONIX also received clearance from Health Canada, which issued a No Objection Letter to the Company’s Clinical Trial Application.
